Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566269 | 0.81 | DRD2 (0.63) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL7524346 | 0.80 | ADRA1A (0.57) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6197779 | 0.80 | DRD2 (0.55) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7677837 | 0.78 | DRD2 (0.59) | DRD2ADRA1ASIGMAR1OPRL1 | |
| SCHEMBL7966084 | 0.78 | ADRA1D (0.66) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL7681665 | 0.78 | DRD2 (0.56) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL6215791 | 0.77 | DRD2 (0.58) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6216974 | 0.77 | DRD2 (0.57) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7234672 | 0.76 | DRD2 (0.59) | DRD2ADRA1ASIGMAR1ADRA1DADRA1B | |
| SCHEMBL7079236 | 0.76 | DRD2 (0.57) | DRD2ADRA1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| EP-1021185-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | DRD2 1498/4885ADRA1A 4/4885SIGMAR1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.